DARE (Dare Bioscience) YoY EBITDA Growth: 60.67% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DARE Dare Bioscience Inc DARE
28 GF Score
Price $0.83
GF Value $2.38
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Dare Bioscience YoY EBITDA Growth?

Dare Bioscience DARE +7.50% 28 YoY EBITDA Growth is 60.67% as of Jun. 2026. GuruFocus rates DARE with a GF Score™ of 28/100 and a GF Value™ of $2.38 (Possible Value Trap). The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Dare Bioscience's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 60.67%.

Dare Bioscience's EBITDA per Share for the three months ended in Jun. 2026 was $-0.14.

Dare Bioscience YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Dare Bioscience's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dare Bioscience YoY EBITDA Growth Chart

Dare Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.45 42.23 5.57 92.37 -195.25

Dare Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.72 -114.10 92.91 66.88 60.67
DARE
28GF Score
Dare Bioscience Inc DARE
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dare Bioscience YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Dare Bioscience's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.933--0.316)/ | -0.316 |
=-195.25 %

Dare Bioscience's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.14--0.356)/ | -0.356 |
=60.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 60.67% mean?
Dare Bioscience (DARE) has a YoY EBITDA Growth of 60.67% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Dare Bioscience and its competitors.
Is Dare Bioscience's YoY EBITDA Growth too high?
Dare Bioscience's current YoY EBITDA Growth is 60.67%. Overall, Dare Bioscience has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dare Bioscience's YoY EBITDA Growth compare to OTLC and PASG?
Dare Bioscience's YoY EBITDA Growth of 60.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Dare Bioscience and its competitors. Dare Bioscience's current YoY EBITDA Growth is 60.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dare Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Dare Bioscience (DARE) is currently considered Possible Value Trap. The stock's GF Value™ is $2.38, compared to a current price of $0.83 — trading 65.2% below its estimated fair value. The current YoY EBITDA Growth is 60.67%. Dare Bioscience's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Dare Bioscience (DARE), the current YoY EBITDA Growth is 60.67% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dare Bioscience (DARE) Overvalued in 2026?

Based on GuruFocus' analysis, Dare Bioscience stock appears to be undervalued. The current stock price of $0.83 is trading 65.2% below its estimated GF Value™ of $2.38. GuruFocus considers Dare Bioscience to be Possible Value Trap.

Key valuation signals for DARE:

  • YoY EBITDA Growth: 60.67%
  • GF Value™: $2.38 vs. price of $0.83 (65.2% below fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the DARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dare Bioscience Business Description

Address 3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
28GF Score

Get the complete analysis for DARE

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.83
Price
$2.38
GF Value